Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9966071 | 0.91 | PTGS2 (0.36) | PTGS2TLR9TLR8TLR7DHODH | |
| SCHEMBL9963639 | 0.82 | PTGS2 (0.44) | PTGS2TLR9TLR8TLR7 | |
| SCHEMBL14369905 | 0.80 | PTGS2 (0.36) | PTGS2TLR9TLR8TLR7ACKR3 | |
| SCHEMBL9963672 | 0.80 | PTGS2 (0.38) | PTGS2TLR9TLR8TLR7DHODH | |
| SCHEMBL9963660 | 0.78 | ACHE (0.41) | PTGS2TLR9TLR8TLR7ACKR3 | |
| SCHEMBL9963644 | 0.78 | PTGS2 (0.37) | PTGS2TLR9TLR8TLR7 | |
| SCHEMBL9963654 | 0.78 | PTGS2 (0.39) | PTGS2TLR9TLR8TLR7 | |
| SCHEMBL9963617 | 0.78 | PTGS2 (0.47) | PTGS2IDO1ACKR3ABL1 | |
| SCHEMBL9963592 | 0.77 | PTGS2 (0.41) | PTGS2 | |
| SCHEMBL9963641 | 0.77 | CHRM4 (0.35) | PTGS2TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | PTGS2 2872/4885TLR9 3948/4885TLR8 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.